Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - OncoMed Pharmaceuticals Inc | d124790dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 25, 2016
ONCOMED PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35993 | 38-3572512 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
800 Chesapeake Drive
Redwood City, California 94063
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 995-8200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On January 25, 2016, OncoMed Pharmaceuticals, Inc. (the “Company”) issued a press release providing an update regarding the Company’s Phase 2 clinical trial of tarextumab in pancreatic cancer (the “Press Release”). A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1, and the first four paragraphs of the Press Release are incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press release, dated January 25, 2016 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 25, 2016 | ONCOMED PHARMACEUTICALS, INC. | |||||
| By: | /s/ Alicia J. Hager | |||||
| Alicia J. Hager, J.D., Ph.D. Vice President and General Counsel | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press release, dated January 25, 2016 | |